Lithium addition to neuroleptic treatment in chronic schizophrenia: a randomized, double-blind, placebo-controlled, cross-over study. 1995

T Terao, and T Oga, and S Nozaki, and A Ohta, and Y Ohtsubo, and S Yamamoto, and M Zamami, and M Okada
Hitachi Umegaoka Mental Hospital, Japan.

We studied the effect of lithium addition to neuroleptic treatment in chronic schizophrenia, for which contradictory results have been produced in previous studies. Twenty-one chronic schizophrenic inpatients received lithium in a study with randomized, double-blind, placebo-controlled, cross-over design consisting of 8 weeks each of treatment with lithium capsules and identical placebo capsules. The total Brief Psychiatric Rating Scale (BPRS) scores at week 8 of the lithium treatment were improved significantly compared with those at week 8 of the placebo treatment. Of the BPRS subscales, however, only anxiety-depression improved, whereas none of the subscales for anergia, thought disturbance, activation and hostile-suspiciousness improved. There was no significant difference between the total Scale for the Assessment of Negative Symptoms (SANS) scores at any time during lithium and placebo treatment. These results suggest that the addition of lithium to neuroleptic treatment improves anxiety-depression in chronic schizophrenia.

UI MeSH Term Description Entries
D008094 Lithium An element in the alkali metals family. It has the atomic symbol Li, atomic number 3, and atomic weight [6.938; 6.997]. Salts of lithium are used in treating BIPOLAR DISORDER. Lithium-7,Lithium 7
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011569 Psychiatric Status Rating Scales Standardized procedures utilizing rating scales or interview schedules carried out by health personnel for evaluating the degree of mental illness. Factor Construct Rating Scales (FCRS),Katz Adjustment Scales,Lorr's Inpatient Multidimensional Psychiatric Rating Scale,Wittenborn Scales,Edinburgh Postnatal Depression Scale,Mini International Neuropsychiatric Interview
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D012559 Schizophrenia A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior. Dementia Praecox,Schizophrenic Disorders,Disorder, Schizophrenic,Disorders, Schizophrenic,Schizophrenias,Schizophrenic Disorder

Related Publications

T Terao, and T Oga, and S Nozaki, and A Ohta, and Y Ohtsubo, and S Yamamoto, and M Zamami, and M Okada
March 1999, Psychopharmacology,
T Terao, and T Oga, and S Nozaki, and A Ohta, and Y Ohtsubo, and S Yamamoto, and M Zamami, and M Okada
March 2006, International clinical psychopharmacology,
T Terao, and T Oga, and S Nozaki, and A Ohta, and Y Ohtsubo, and S Yamamoto, and M Zamami, and M Okada
June 2002, The Journal of clinical endocrinology and metabolism,
T Terao, and T Oga, and S Nozaki, and A Ohta, and Y Ohtsubo, and S Yamamoto, and M Zamami, and M Okada
February 1986, The American journal of psychiatry,
T Terao, and T Oga, and S Nozaki, and A Ohta, and Y Ohtsubo, and S Yamamoto, and M Zamami, and M Okada
December 1991, Acta neurologica Scandinavica,
T Terao, and T Oga, and S Nozaki, and A Ohta, and Y Ohtsubo, and S Yamamoto, and M Zamami, and M Okada
February 1999, Journal of clinical pharmacy and therapeutics,
T Terao, and T Oga, and S Nozaki, and A Ohta, and Y Ohtsubo, and S Yamamoto, and M Zamami, and M Okada
April 1995, Ugeskrift for laeger,
T Terao, and T Oga, and S Nozaki, and A Ohta, and Y Ohtsubo, and S Yamamoto, and M Zamami, and M Okada
January 2019, Journal of clinical psychopharmacology,
T Terao, and T Oga, and S Nozaki, and A Ohta, and Y Ohtsubo, and S Yamamoto, and M Zamami, and M Okada
January 1981, The American journal of psychiatry,
T Terao, and T Oga, and S Nozaki, and A Ohta, and Y Ohtsubo, and S Yamamoto, and M Zamami, and M Okada
March 2012, Clinical research in cardiology : official journal of the German Cardiac Society,
Copied contents to your clipboard!